Phase II Study of Docetaxel and S-1 (DS) as Neoadjuvant Chemotherapy for Clinical Stage III Resectable Gastric Cancer

[1]  J. Sakamoto,et al.  Phase II trial of paclitaxel and cisplatin as neoadjuvant chemotherapy for locally advanced gastric cancer , 2013, Cancer Chemotherapy and Pharmacology.

[2]  T. Yoshikawa,et al.  Gastrointestinal cancer: Adjuvant chemotherapy after D2 gastrectomy for gastric cancer , 2012, Nature Reviews Clinical Oncology.

[3]  E. Chiorean.  Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial , 2012 .

[4]  T. Yoshikawa,et al.  A comparison of multimodality treatment: two and four courses of neoadjuvant chemotherapy using S-1/CDDP or S-1/CDDP/docetaxel followed by surgery and S-1 adjuvant chemotherapy for macroscopically resectable serosa-positive gastric cancer: a randomized phase II trial (COMPASS-D trial). , 2012, Japanese journal of clinical oncology.

[5]  Y. Ohashi,et al.  Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Thigpen.  Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial , 2011 .

[7]  Japanese Gastric Cancer Association.  Japanese gastric cancer treatment guidelines 2010 (ver. 3) , 2011, Gastric Cancer.

[8]  I. Endo,et al.  Phase II study of biweekly docetaxel and S-1 combination chemotherapy as first-line treatment for advanced gastric cancer , 2011, Cancer Chemotherapy and Pharmacology.

[9]  H. Putter,et al.  Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. , 2010, The Lancet. Oncology.

[10]  A. Ohtsu,et al.  Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. , 2009, The Lancet. Oncology.

[11]  Takeshi Sano,et al.  Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer , 2009, The British journal of surgery.

[12]  E. Oki,et al.  Phase II Study of Biweekly Docetaxel and S-1 Combination Therapy for Advanced or Recurrent Gastric Cancer , 2009, Oncology.

[13]  T. Eberlein.  D2 Lymphadenectomy Alone or with Para-aortic Nodal Dissection for Gastric Cancer , 2009 .

[14]  Yasuo Ohashi,et al.  Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. , 2007, The New England journal of medicine.

[15]  A. Nashimoto,et al.  A phase II study of preoperative chemotherapy (CX) with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancer: JCOG 0210 , 2007 .

[16]  C. V. D. van de Velde,et al.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.

[17]  T. Takayama,et al.  Neoadjuvant chemotherapy with S-1 and CDDP in advanced gastric cancer , 2006, Journal of Cancer Research and Clinical Oncology.

[18]  H. Narahara,et al.  Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer , 2006, British Journal of Cancer.

[19]  Kazuhiro Yoshida,et al.  Phase II Study of Docetaxel and S-1 Combination Therapy for Advanced or Recurrent Gastric Cancer , 2006, Clinical Cancer Research.

[20]  E. Tokunaga,et al.  Phase I study of S-1 and biweekly docetaxel combination chemotherapy for advanced and recurrent gastric cancer. , 2006, Oncology reports.

[21]  M. Fukushima,et al.  Increased Antitumor Activity in Combined Treatment TS-1 and Docetaxel , 2005, Oncology.

[22]  Y. Maehara.  S-1 in gastric cancer: a comprehensive review , 2003, Gastric Cancer.

[23]  J. Ferlay,et al.  Erratum: Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer, 83, 18–29 (1999). , 1999, International journal of cancer.

[24]  J. Ferlay,et al.  Estimates of the worldwide mortality from 25 cancers in 1990 , 1999, International journal of cancer.